Federal policies and agency actions related to peptide therapies, precision medicine, physician-supervised access, pharmaceutical quality and safety, drug compounding, clinical research, and healthcare innovation.
Source-reported fields
Filing overview
- Type
- Registration
- Posted
- Jul 22, 2026
- Income
- Not reported
- Expenses
- Not reported
- Registrant
- THORNROSE VENTURES
- Client
- MINO, LLC
- Filing UUID
- 186c5f25-5f9f-4ef5-b1ab-d7d42d4fd836
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Federal policies and agency actions related to peptide therapies, precision medicine, physician-supervised access, pharmaceutical quality and safety, drug compounding, clinical research, and healthcare innovation.
Federal policies and agency actions related to peptide therapies, precision medicine, physician-supervised access, pharmaceutical quality and safety, drug compounding, clinical research, and healthcare innovation.
Federal policies and agency actions related to peptide therapies, precision medicine, physician-supervised access, pharmaceutical quality and safety, drug compounding, clinical research, and healthcare innovation.
Federal policies and agency actions related to peptide therapies, precision medicine, physician-supervised access, pharmaceutical quality and safety, drug compounding, clinical research, and healthcare innovation.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.